This
warning letter summarizes significant violations of current good manufacturing
practice (CGMP) regulations for finished pharmaceuticals. See 21 CFR, parts 210
and 211.
Because
your methods, facilities, or controls for manufacturing, processing, packing,
or holding do not conform to CGMP, your drug products are adulterated within
the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act
(FD&C Act), 21 U.S.C. 351(a)(2)(B).
During
our inspection, our investigator observed specific violations including, but
not limited to, the following.
1. Your
firm does not have, for each batch of drug product, appropriate laboratory
determination of satisfactory conformance to final specifications for the drug
product, including the identity and strength of each active ingredient, prior
to release (21 CFR 211.165(a)).
For example,
you have not tested any of the (b)(4) patches you manufacture
to determine the identity, purity, or potency of each active ingredient prior
to release.
2. Your
firm failed to test samples of each component for conformity with all
appropriate written specifications for purity, strength, and quality (21 CFR
211.84(d)(2)).
For
example, you have not tested incoming active pharmaceutical ingredients or
other components you use in manufacturing (b)(4) patches to
determine their identity, purity, and potency.
3. Your firm failed to
establish and follow written procedures for cleaning and maintenance of
equipment (21 CFR 211.67(b)).
For
example, you did not have cleaning procedures for the manufacturing equipment
you use to make (b)(4) patches. During the inspection, our
investigator observed rust and unidentified (b)(4) residue on
your (b)(4) and other manufacturing equipment.
4. Your
firm failed to establish written procedures to prevent mix-ups and cross
contamination by physical or spatial separation from operations on other drug
products (21 CFR 211.130(a)).
For
example, our investigator observed (b)(4) of unlabeled (b)(4) patches
of different sizes and colors co-mingled on a table awaiting final packaging,
which could lead to product mix-ups during packaging operations.
5. Your
firm delayed, denied, or limited an inspection, or refused to permit the FDA
inspection.
You
limited FDA’s inspection because you refused to provide FDA with records
related to suppliers of components and products that you repackage at your
facility.
Although
you provided the names of two of your suppliers, you refused to provide
documentation to show the identities of components or products you obtained
from these suppliers, or whether these suppliers performed appropriate release
testing on the materials before you received them. Refusing to provide records
requested by the FDA investigator that FDA has authority to inspect is
considered limiting an inspection.
When an
owner, operator, or agent delays, denies, limits, or refuses an inspection, the
drugs may be deemed adulterated under section 501(j) of the FD&C Act. See
FDA’s guidance, Circumstances that Constitute Delaying, Denying,
Limiting, or Refusing a Drug Inspection, available online at
www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM360484.pdf.
FDA
Sampling and Testing of your Products
FDA
collected samples of your product during an inspection of a customer’s
facility. FDA tested samples of (b)(4) ((b)(4) ointment (b)(4)%).
FDA laboratory analysis showed that they samples of your product were
sub-potent for the labeled active ingredient, containing an average potency of
69.0% of the label claim.
Consultant
Recommended
In your
response to the Form FDA 483, you committed to (b)(4). In addition,
you committed to engaging a contract laboratory to test drug products
distributed to the United States in 2016, and you provided some reports of test
results. However, the reports you provided are inadequate because they omit
critical information about the tests your contract laboratory performed, such
as relevant drug product specifications, and details about the methods used.
Conclusion
Violations
cited in this letter are not intended as an all-inclusive list. You are
responsible for investigating these violations, for determining the causes, for
preventing their recurrence, and for preventing other violations.
Source: FDA
www.gmpviolations.comGMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news.
0 comments:
Post a Comment